by Nicola Blackburn | Jul 4, 2023
Researchers at the Garvan Institute have developed a novel way to monitor drug response and resistance in pancreatic cancer, utilizing a mouse model that allows for the real time visualisation of the effect of drug treatment within tumours. The team at the Garvan...
by Nicola Blackburn | Dec 28, 2022
2022 was another year of facing and overcoming challenges for people around the world. As we move into a new year, it is a good time to reflect on achievements and accomplishments. Throughout the year, the APGI has continued to support Pancreatic Cancer research...
by Nicola Blackburn | Nov 16, 2022
In recognition of Pancreatic Cancer Awareness Month, this November iconic buildings over Australia will light up purple to raise awareness for the disease and to celebrate and honour survivors and loved ones. Pancreatic cancer is the third leading cause of cancer...
by Nicola Blackburn | Sep 9, 2022
A new clinical trial for people with advanced pancreatic cancer, has now commenced in Australia. The trial led by Amplia Therapeutics, in collaboration with Professor Paul Timpson from the Invasion and Metastasis Lab at The Garvan Institute of Medical Research, will...
by Gloria Jeong | Jul 6, 2022
Pancreatic cancer is one of the most aggressive cancers and five-year survival rates are just 10%. A very small number of patients live longer, with less than 2% surviving more than 10 years after diagnosis. Researchers have been working to understand how this cancer...
by Gloria Jeong | Jun 16, 2022
The Avner Australian Pancreatic Cancer Matrix Atlas group (APMA) will investigate a potential new way to improve immunotherapy outcomes for patients with pancreatic cancer using a class of drug that can reduce the metabolic rewiring of the cancer cells thanks to a...
